Lenoxin® Mite (Digoxin)

Digoxin inhibits the sodium‑potassium ATPase pump on cardiac cells, raising intracellular sodium. This change reduces the activity of the sodium‑calcium exchanger, leading to increased calcium within the heart muscle, which strengthens contraction. It also enhances vagal tone, slowing conduction through the atrioventricular node and helping to regulate heart rate.

The appropriate dose of Lenoxin® Mite is individualized by the prescribing clinician based on the patient’s age, renal function, electrolyte status, and therapeutic response. Dosage adjustments are made after evaluating serum digoxin concentrations and clinical effect, and patients should follow the prescriber’s specific instructions.

Safety of digoxin in pregnancy and lactation has not been definitively established. It may be used if the potential benefit justifies the potential risk to the fetus or infant. Clinicians should assess each case carefully, and breastfeeding mothers should discuss possible exposure with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Lenoxin® Mite. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Digoxin provides a unique positive inotropic effect and rate‑controlling properties not shared by many other heart‑failure agents such as ACE inhibitors or beta‑blockers. While it can improve symptoms and reduce hospitalizations, it does not replace guideline‑directed therapies and is typically added when additional control of heart rate or contractility is needed.

Lenoxin® Mite should be stored at temperatures below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and avoid storing it in bathrooms or other humid environments.

Lenoxin® Mite is taken orally, usually with or without food as directed by the prescriber. The tablet should be swallowed whole with a glass of water. Patients should not crush, chew, or split the tablet unless specifically instructed by a healthcare professional.

The most serious risks include digoxin toxicity, which can manifest as severe cardiac arrhythmias, marked bradycardia, and life‑threatening conduction disturbances. Electrolyte imbalances, especially low potassium or high calcium, can increase toxicity risk. Prompt medical evaluation is essential if symptoms such as visual changes, nausea, or irregular heartbeat occur.

Lenoxin® Mite should be avoided in patients with known hypersensitivity to digoxin or other cardiac glycosides, in those with uncontrolled ventricular arrhythmias, and in individuals with severe renal impairment without appropriate dose adjustment. Clinicians should also exercise caution in patients with significant electrolyte disturbances or advanced heart block.